Research progress of PI3K/Akt pathway in diabetic cardiomyopathy
10.3969/j.issn.1001-1978.2019.09.005
- Author:
Jia-Xi HUANG
1
Author Information
1. College of Pharmacy
- Publication Type:Journal Article
- Keywords:
Blood glucose;
Diabetic cardiomyopathy;
Endothelial cells;
Inflammation;
Lipid metabolism;
PDK/Akt
- From:
Chinese Pharmacological Bulletin
2019;35(9):1202-1205
- CountryChina
- Language:Chinese
-
Abstract:
Diabetic cardiomyopathy(DCM) is a type of primary cardiomyopathy caused by diabetes, changing in the structure and function of the myocardium, which is distinguished from secondaiy cardiomyopathy resulted from coronary atherosclerosis, hypertension, and viruses. Phosphatidylinositol 3-kinase (PI3K)/Akt is an important signal transduction pathway in human body involved in the growth and reproduction of body. Regulatory factors of the PDK/Akt signaling pathway include silencing information regulator 1, homologous phosphatase-tensin, glycogen synthase kinase 3(3 and the rapamycin target protein. The role of PDK/Akt signaling pathway in the pathogenesis of DCM includes regulating blood sugar level, regulating lipid metabolism, protecting endothelial cells, reducing inflammatory response , improving cardiac function, resisting fibrosis, and regulating myocardial apoptosis. The development of PI3K-Akt signaling pathway inhibitors provides the possibility for PDK-Akt pathway targeted therapy. This article reviews the progression of the PDK/Akt pathway in DCM.
